STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.

Status: Completed
Location: See all (11) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The aim of the study is to test if intracerebral haemorrhage (ICH) patients who have contrast extravasation on computed tomography angiography, the spot sign, have lower rates of haematoma growth when treated with tranexamic acid within 4.5 hours of stroke onset, compared to placebo.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients presenting with an acute ICH

• Contrast extravasation within the haemorrhage, spot sign, evaluated from the CTA according to three criteria, all of which must be present:

‣ Serpiginous or spot-like appearance within the margin of a parenchymal haematoma without connection to an outside vessel;

⁃ The density (in Hounsfield units) should be greater than that of the background haematoma (site investigators are not required to document the density); and

⁃ No hyperdensity at the corresponding location on non-contrast CT.

• Age ≥18 years

• Treatment can commence within 1 hour of initial CT and within 4.5 hours of symptom onset (or in patients with unknown time of symptom onset, the time patient was last known to be well)

• Informed consent has been received in accordance to local ethics committee requirements

Locations
Other Locations
Australia
Royal Adelaide Hospital
Adelaide
Box Hill Hospital
Box Hill
Western Hospital
Footscray
Frankston Hospital
Frankston
Gosford Hospital
Kanwal
The Royal Melbourne Hospital
Melbourne
John Hunter Hospital
Newcastle
Royal Prince Alfred Hospital
Sydney
St. Vincent's Hospital
Sydney
Westmead Hospital
Westmead
Finland
Helsinki University Central Hospital
Helsinki
Time Frame
Start Date: 2012-12
Completion Date: 2019-12
Participants
Target number of participants: 100
Treatments
Active_comparator: Tranexamic Acid
Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
Placebo_comparator: Placebo
Intravenous placebo in 100 mL 0.9% NaCl over 10 minutes followed by 500 mL 0.9% NaCl infusion over 8 hours.
Sponsors
Leads: Neuroscience Trials Australia

This content was sourced from clinicaltrials.gov